Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Neuropharmacology. 2022 Aug 22;218:109233. doi: 10.1016/j.neuropharm.2022.109233

Fig. 3. The PPARγ antagonist blocks ELB00824 prevention of OIPN.

Fig. 3.

The involvement of PPARγ in the preventive effect of ELB00824 (ELB) on cold hyperalgesia (A) and mechanical allodynia (B) was identified at the end of oxaliplatin treatment period in the chronic model of OIPN. The box-and-whiskers plots show minimum, maximum, median and 25th and 75th percentiles. Inter-group comparison was done using one-way ANOVA, followed by Dunn’s test. *: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.001; ****: p ≤ 0.01; vs Veh Control group. #: p ≤ 0.05; ##: p ≤ 0.01; ###: p ≤ 0.001 vs ELB 30 + Oxa group. Dashed line is the mean value of Oxa control group at the end of the oxaliplatin treatment period in the chronic OIPN model.